Harmony Biosciences Holdings, Inc. (HRMY) earnings
HRMY earnings moved a median of +2.61% by the close. Quarterly and annual HRMY reports and results, each read against the price at its own news timestamp. Back to the HRMY overview →
24 measured HRMY earnings events.
Where these HRMY earnings landedvs 24 measured HRMY earnings reactions
| Middle 50% of HRMY earnings reactions | +0.26% to +5.42% |
|---|---|
| Median reaction (to close) | +2.61% |
| Measured reactions | 24 |
Point-in-time · zero look-ahead
Half of the 24 HRMY earnings events with a measured close landed between +0.26% and +5.42%; 79% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Harmony Biosciences Hold For: Jun 30 | SEC filing · Form 10-Q | -1.85% | +2.62% | |
| Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile | Press release | -1.85% | +2.62% | |
| Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026 | Press release | +0.42% | +10.76% | |
| Form 10-Q Harmony Biosciences Hold For: Mar 31 | SEC filing · Form 10-Q | +4.06% | +8.53% | |
| Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | +0.61% | +0.28% | |
| Form 10-K Harmony Biosciences Hold For: Dec 31 | SEC filing · Form 10-K | -4.16% | +1.92% | |
| Form 10-Q Harmony Biosciences Hold For: Sep 30 | SEC filing · Form 10-Q | -5.25% | +4.81% | |
| Form 10-Q Harmony Biosciences Hold For: Jun 30 | SEC filing · Form 10-Q | -1.42% | +2.07% | |
| Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025 | Press release | +0.94% | +4.08% | |
| Form 10-Q Harmony Biosciences Hold For: Mar 31 | SEC filing · Form 10-Q | +2.30% | +3.02% | |
| Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025 | Press release | -0.36% | +0.00% | |
| Form 10-K Harmony Biosciences Hold For: Dec 31 | SEC filing · Form 10-K | +2.66% | +6.76% | |
| Form 10-Q Harmony Biosciences Hold For: Sep 30 | SEC filing · Form 10-Q | -2.87% | +10.40% | |
| HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS | Press release | -2.87% | +10.40% | |
| HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON OCTOBER 29, 2024 | Press release | +0.69% | -2.02% | |
| Form 10-Q Harmony Biosciences Hold For: Jun 30 | SEC filing · Form 10-Q | -0.91% | +2.59% | |
| Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028 | Press release | -0.91% | +2.59% | |
| HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 6, 2024 | Press release | +0.42% | +0.21% | |
| Form 10-Q Harmony Biosciences Hold For: Mar 31 | SEC filing · Form 10-Q | +0.05% | -2.34% | |
| HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 | Press release | -0.37% | +0.81% | |
| Form 10-K/A Harmony Biosciences Hold For: Dec 31 | SEC filing · Form 10-K | -0.38% | -5.28% | |
| Form 10-K Harmony Biosciences Hold For: Dec 31 | SEC filing · Form 10-K | -4.93% | -4.81% | |
| Form 10-Q Harmony Biosciences Hold For: Sep 30 | SEC filing · Form 10-Q | +2.24% | +5.42% | |
| Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results | Press release | +2.24% | +5.42% |
Keep exploring
More HRMY: analyst actions → · SEC filings → · HRMY overview →